The risk of thromboembolism in relation to in vitro fertilization
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, přehledy
PubMed
31324115
PII: 113052
Knihovny.cz E-zdroje
- Klíčová slova
- assisted reproduction, in vitro fertilization, ovarian hyperstimulation syndrome, thromboembolism,
- MeSH
- fertilizace in vitro škodlivé účinky MeSH
- fibrinolytika aplikace a dávkování MeSH
- hematologické komplikace těhotenství farmakoterapie etiologie MeSH
- heparin nízkomolekulární aplikace a dávkování MeSH
- indukce ovulace MeSH
- lidé MeSH
- ovariální hyperstimulační syndrom komplikace MeSH
- přenos embrya MeSH
- těhotenství MeSH
- tromboembolie farmakoterapie etiologie prevence a kontrola MeSH
- úhrn těhotenství na počet žen v reprodukčním věku MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- fibrinolytika MeSH
- heparin nízkomolekulární MeSH
OBJECTIVE: Summary of available literature concerning recommendation of antithrombotic prophylaxis in the infertility treatment by in vitro fertilization (IVF) and in pregnancies after IVF. DESIGN: Review article. SETTINGS: Department of Obstetrics and Gynecology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc; Institute of Medical Genetics, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc. METHODS: Analysis of literary sources and databases Medline, Web of Science, Scholar Google, 2010-2018. CONCLUSION: The incidence of thromboembolism in the first trimester of pregnancy after IVF is 0.2% e. g. 10-times higher compared to normal pregnant population. Pregnancies after IVF are complicated in 6-7% by ovarian hyperstimulation syndrome (OHSS), they then have the risk of venous thromboembolism (VTE) 1.7% in the first trimester, what is 100-times higher as compared to the general population. Women after IVF without OHSS have a 5-times higher risk of VTE compared to the general population. To lower the risk of thromboembolism during treatment, use of low dose gonadotrophin (mild) stimulation protocols, prioritization of antagonistic stimulation protocols, avoidance of OHSS using GnRH agonists instead of hCG, cryo embryotransfer in natural cycles, reduction of incidence of multiple pregnancy by single embryo transfer, use of prophylactic and therapeutic low molecular weight heparin (LMWH) is recommended. These strategies can reduce the risk of thromboembolism. The LMWH application is suitable in pregnant women in the first trimester of pregnancy after IVF where OHSS was present.